Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026
First-in-human Phase 1 presentation to feature ATNM-400 clinical data in metastatic castration-resistant prostate cancer, advancing a differentiated approach beyond PSMA Preclinical presentation to feature ATNM-400 studies in KRAS- and ALK-driven non-small cell lung cancer, exploring its...
Covered in this story
Call it yourself
No calls on $ALK yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Alaska Air Group →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.